MSLN and ovarian carcinoma: Another mesothelin-targeting approach is being investigated in a phase I clinical trial involving patients with recurrent mesothelin-expressing platinum-resistant ovarian cancer, and this study will test the efficacy of anetumab ravtansine in combination with polyethylene glycol (PEG) PEGylated liposomal doxorubicin (ClinicalTrials.gov identifier: NCT02751918).